Drug updated on 5/17/2024
Dosage Form | granules (oral; 2 g/packet) |
Drug Class | Nitroimidazole antimicrobials |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.
- Indicated for the treatment of trichomoniasis in patients 12 years of age and older.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Secnidazole (Solosec) is indicated for the treatment of bacterial vaginosis and trichomoniasis in individuals 12 years of age and older. It has comparable efficacy to metronidazole, a commonly used treatment for these conditions.
- Two studies providing comprehensive information about secnidazole's effectiveness and safety profile were reviewed.
- The effectiveness of secnidazole varies based on the individual's history of bacterial vaginosis; it benefits more significantly those with three or fewer episodes in the last year than those with four or more episodes.
- Ornidazole appears superior to secnidazole in clinical cure rates at the 4th week after treatment, suggesting that while secnidazole is an effective option, ornidazole could potentially yield better outcomes at this specific follow-up interval.
- No significant adverse events associated with Solosec were reported in the studies. However, detailed specifics regarding these potential adverse events were not elaborated upon within the studies' scope.
- A clear advantage exists when using a 2g dose over a 1g dose concerning its effectiveness, without mentioning any corresponding increase in adverse events, indicating a favorable dose-response relationship.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Solosec (secnidazole) Prescribing Information. | 2022 | Lupin Pharmaceuticals Inc., Baltimore, MD |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Secnidazole for treatment of bacterial vaginosis: a systematic review. | 2019 | BMC Womens Health |
Efficacy and safety of single dose of oral secnidazole 2 g in treatment of bacterial vaginosis: a systematic review and meta-analysis. | 2019 | European Journal of Obstetrics & Gynecology and Reproductive Biology |